By Curtana Pharmaceuticals Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, is proud to partner with the National Brain Tumor Society (NBTS) to shine a light on glioblastoma (GBM), the most common, treatment-resistant, and deadliest type of...
|
By Curtana Pharmaceuticals Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to CT-179, the company's lead Olig2 inhibitor, for...
|
